Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell today even though the company beat expectations on Wall Street with its second quarter results. The Warren, N.J.-based company posted a net loss of -$3.9 million with no sales for the 3 months ended June 30, for bottom-line growth of 23% compared with the same period last year. Adjusted to […]
MassDevice Earnings Roundup
Pulmatrix beats Q2 EPS by a penny
Shares in Pulmatrix (NSDQ:PULM) fell last week even though the biopharmaceutical company beat expectations on Wall Street with its second quarter results. The Lexington, Mass.-based company posted a net loss of -$5.6 million with no revenue for the 3 months ended June 30, for bottom-line growth of 39% compared with the same period last year. Adjusted […]
Cerus posts Street-beating Q2 results
Shares in Cerus (NSDQ:CERS) fell today despite the company beating expectations on Wall Street with its second quarter results. The Concord, Calif.-based company posted a net loss of -$17.1, or -16¢ per share, on sales of $9.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales growth of 3% compared […]
Insulet Q2 sales tops estimates
Shares in Insulet (NSDQ:PODD) rose today after the company met earnings expectations on Wall Street and beat sales estimates with its second quarter results. The Billerica, Mass.-based company posted a net loss of -$7.8 million, or -13¢ per share, on sales of $109.8 million for the 3 months ended June 30, for bottom-line loss of -85% […]
Glaukos shares fall on Q2 sales, EPS miss
Shares in Glaukos (NYSE:GKOS) have fallen today after the diabetes-focused medical device maker missed expectation on Wall Street with its 2nd quarter earnings results. The San Clemente, Calif.-based company posted losses of $3.3 million, or 10¢ per share, on sales of $41.3 million for the 3 months ended June 30, seeing profits swing 241.6% into losses […]
Teva lowers outlook after Q2 EPS misses estimates
(Reuters) – Israeli drugs group Teva Pharmaceuticals (NYSE:TEVA) reported a steeper than expected drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent. Along with a substantial reduction in its 2017 outlook, shares in the world’s largest generics drugmaker tumbled 16.5 percent in Tel Aviv […]
Pacira misses on Q2 sales, earnings
Shares in Pacira Pharmaceuticals (NSDQ:PCRX) fell slightly today after the pharmaceutical company missed expectations on Wall Street with its second quarter results. The Parsippany, N.J.-based company posted a net loss of -$19.7 million, or -49¢ per share, on sales of $70.9 million for the 3 months ended June 30, for bottom-line loss of -148% on sales […]
Aerie Pharmaceuticals misses Q2 EPS by a penny
Shares in Aerie Pharmaceuticals (NSDQ:AERI) held steady today after the pharmaceutical company missed EPS estimates on Wall Street with its second quarter results. The Irvine, Calif.-based company posted a net loss of -$28.4 million, or -82¢ per share, with its bottom line down -22.5% compared with the same period last year. Adjusted to exclude 1-time items, […]
Intersect ENT tops EPS, sales estimates in Q2
Shares in Intersect ENT (NSDQ:XENT) surged today after the drug-device company beat expectations on Wall Street with its second quarter results. The Menlo Park, Calif.-based company posted a loss of -$2.3 million on sales of $24 million for the 3 months ended June 30, for bottom-line growth of 62% on sales growth of 24% compared […]
Awaiting tax reform clarity, Pfizer delays potential M&A
(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value. The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull […]
